mupirocin

Mupirocin (BRL-4910A) is a RNA synthetase inhibitor antibacterial. It has shown excellent activity against gram-positive staphylococci and streptococci.

Mupirocin calcium hydrate is an antibiotic produced by Pseudomonas fluorescens, showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria

Pseudomonic acid C is the analogue of Pseudomonic Acid D which is an antibiotic agent from Pseudomonas fluorescens.

Mupirocin calcium (BRL-4910A, Pseudomonic acid), an orally active antibiotic derived from Pseudomonas fluorescens, exerts its antimicrobial effects by reversibly inhibiting isoleucyl-transfer RNA. This action impedes bacterial protein and RNA synthesis, demonstrating its effectiveness [1] [2].

AVX 13616, Avexa's leading antibacterial candidate, demonstrates significant in vivo antibacterial efficacy, especially against drug-resistant Staphylococcus pathogens, with an IC50 value of 2-4 µg/ml (MICs) and is targeted as an antibacterial agent. Comparable in activity to mupirocin within a nasal decolonization model, AVX13616 necessitated only a single application for effectiveness. This compound, alongside others, exhibited broad-spectrum antibacterial action, achieving MICs of 2-4 micrograms per milliliter against various isolates, including S. aureus, coagulase-negative staphylococci, enterococci, MRSA, VISA, and VRSA. Aimed for topical use and the treatment of wound infection or catheter-related infections, a solitary 5% (w/w) AVX13616 application (roughly equivalent to 2% mupirocin) proved as efficacious as twice-daily 2% mupirocin over five days in decolonizing MRSA in mice.

Boeravinone B (Standard) is a reference standard for research and analysis in studies involving Boeravinone B. Boeravinone B, a novel efflux pump inhibitor, apart from inhibiting the MdeA mediated efflux, also significantly inhibit the biofilm formation of S. aureus, boeravinone B may be used in combination with mupirocin for further development. Boeravinone B exhibits significant anti-inflammatory activity (56.6% at 50 mg/kg) when evaluated in an in vivo carrageenan-induced rat paw model.

Boeravinone B, a novel efflux pump inhibitor, apart from inhibiting the MdeA mediated efflux, also significantly inhibit the biofilm formation of S. aureus, boeravinone B may be used in combination with mupirocin for further development. Boeravinone B exh